18566257. CYCLIC PEPTIDE ANTIBIOTICS simplified abstract (GENENTECH, INC.)

CYCLIC PEPTIDE ANTIBIOTICS

Organization Name

GENENTECH, INC.

Inventor(s)

Christian Nathaniel Cunningham of Oakland CA (US)

Jian Mehr-Dean Payandeh of Belmont CA (US)

Steven Thomas Rutherford of El Granada CA (US)

Kelly Marie Colvin Storek of Belmont CA (US)

Patrick C. Reid of Kanagawa (JP)

Hayato Yanagida of Kanagawa (JP)

Junichi Nishikawa of Kanagawa (JP)

CYCLIC PEPTIDE ANTIBIOTICS - A simplified explanation of the abstract

This abstract first appeared for US patent application 18566257 titled 'CYCLIC PEPTIDE ANTIBIOTICS

• • Simplified Explanation:**

This patent application discloses antibacterial compound peptides that target Gram-negative bacteria by inhibiting a membrane protein called BAM A. The application also includes pharmaceutical compositions and treatment methods using these compounds.

• • Key Features and Innovation:**
• Antibacterial compound peptides targeting Gram-negative bacteria
• Inhibition of BAM A membrane protein
• Pharmaceutical compositions for treatment
• Novel method of action against bacteria

• • Potential Applications:**
• Antibacterial treatments
• Pharmaceutical industry
• Healthcare sector

• • Problems Solved:**
• Addressing antibiotic resistance in Gram-negative bacteria
• Providing alternative treatment options
• Targeting specific membrane proteins for antibacterial activity

• • Benefits:**
• Effective against Gram-negative bacteria
• Potential for new antibiotic development
• Targeted treatment approach

• • Commercial Applications:**
• Antibacterial drug development
• Pharmaceutical manufacturing
• Healthcare products market

• • Questions about Antibacterial Compound Peptides:**

1. How do these compound peptides differ from traditional antibiotics?

  - These compound peptides target specific membrane proteins in Gram-negative bacteria, offering a novel mechanism of action.

2. What potential challenges could arise in developing pharmaceutical compositions based on these peptides?

  - Challenges may include formulation stability, regulatory approval, and scalability for mass production.

Original Abstract Submitted

Provided herein are antibacterial compound peptides active against Gram-negative bacteria. In various embodiments, the compounds act by inhibition of BAM A membrane protein. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.